Best deals to access real time data! |
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 80.03 ▲ 0.20 (0.25%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN | Company Description |
|---|---|---|---|---|---|
| Merck & Company (New) | MRK | NYSE | Ordinary Share |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.4 | +0.5% | 79.83 | 80.03 | 79.15 | 79.25 | 79.43 | 17:02:12 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 52,737 | 7,386,060 | $ 79.7393 | $ 588.96M | 12.67M | 52.83 - 80.20 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:53:25 | priorref | 1,694 | $79.83 | USD |
| Industry Sector |
|---|
| Drug Manufacturers - Major |
Merck & Company (New) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 207.59B | 2.6B | $ 2.39B | 0.88 | 87.30 | 2.69B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 2.20 | 2.76% | 03/14/2019 | - | 115.80% |
Merck & Company (New) News
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp. PR Newswire (US) • Thu Feb 21, 2019 1:51 PM (4 hours ago)
Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders ... PR Newswire (US) • Thu Feb 21, 2019 8:20 AM (10 hours ago)
Merck to Buy Immune Design for $5.85 A Share Dow Jones News • Thu Feb 21, 2019 7:33 AM (11 hours ago)
Merck Gets FDA Priority Review for Keytruda in Small Cell Lung Cancer Dow Jones News • Wed Feb 20, 2019 8:06 AM (1 day ago)
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy... Business Wire • Wed Feb 20, 2019 6:45 AM (1 day ago)
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) • Tue Feb 19, 2019 5:37 PM (2 days ago)
Merck: Keytruda Didn't Meet Co-Primary Endpoints in Phase 3 Trial for Hepatocellular Carcinoma Dow Jones News • Tue Feb 19, 2019 4:53 PM (2 days ago)
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRK Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 79.13 | 80.2 | 77.51 | 78.8305 | 8M | 9M | 8M | 0.7 | 0.88% |
| 1 Month | 75.16 | 80.2 | 72.05 | 75.9254 | 8M | 21M | 12M | 4.67 | 6.21% |
| 3 Months | 77.19 | 80.2 | 70.08 | 75.6988 | 8M | 32M | 13M | 2.64 | 3.42% |
| 6 Months | 68.87 | 80.2 | 66.1 | 73.9938 | 4M | 32M | 11M | 10.96 | 15.91% |
| 1 Year | 54.6 | 80.2 | 52.83 | 67.1004 | 4M | 32M | 10M | 25.23 | 46.21% |
| 3 Years | 50.56 | 80.2 | 50.0901 | 62.7041 | 2M | 69M | 9M | 29.27 | 57.89% |
| 5 Years | 56.24 | 80.2 | 45.69 | 60.1186 | 2M | 69M | 10M | 23.59 | 41.95% |
Merck & Company (New) Description
| Merck & Co Inc is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. |
